Viking Therapeutics to Report Financial Results for Third Quarter 2024 on October 23, 2024
Viking Therapeutics (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on developing novel therapies for metabolic and endocrine disorders, has announced it will release its financial results for the third quarter of 2024 after market close on Wednesday, October 23, 2024. The company will host a conference call to discuss these results and provide general corporate updates at 4:30 p.m. Eastern Time on the same day.
To participate in the conference call, U.S. callers can dial (844) 850-0543, while international callers should use (412) 317-5199. A telephone replay will be available until October 30, 2024, accessible by dialing (877) 344-7529 from the U.S. or (412) 317-0088 from outside the U.S., using the replay access code #9473630. The call can also be accessed via webcast on Viking's website, with an archive available for 30 days.
Viking Therapeutics (NASDAQ: VKTX), un'azienda biofarmaceutica in fase clinica focalizzata sullo sviluppo di nuove terapie per disturbi metabolici ed endocrini, ha annunciato che pubblicher脿 i suoi risultati finanziari per il terzo trimestre del 2024 dopo la chiusura del mercato il mercoled矛 23 ottobre 2024. L'azienda organizzer脿 una conferenza telefonica per discutere di questi risultati e fornire aggiornamenti aziendali generali alle 16:30 ora orientale dello stesso giorno.
Per partecipare alla conferenza telefonica, i chiamanti statunitensi possono comporre (844) 850-0543, mentre i chiamanti internazionali dovrebbero usare (412) 317-5199. Una registrazione telefonica sar脿 disponibile fino al 30 ottobre 2024, accessibile componendo (877) 344-7529 dagli Stati Uniti o (412) 317-0088 dall'estero, utilizzando il codice di accesso alla registrazione #9473630. La chiamata pu貌 essere anche ascoltata tramite webcast sul sito web di Viking, con un archivio disponibile per 30 giorni.
Viking Therapeutics (NASDAQ: VKTX), una empresa biofarmac茅utica en etapa cl铆nica enfocada en el desarrollo de nuevas terapias para trastornos metab贸licos y endocrinos, ha anunciado que publicar谩 sus resultados financieros para el tercer trimestre de 2024 despu茅s del cierre del mercado el mi茅rcoles 23 de octubre de 2024. La empresa llevar谩 a cabo una conferencia telef贸nica para discutir estos resultados y proporcionar actualizaciones corporativas generales a las 4:30 p.m. Hora del Este del mismo d铆a.
Para participar en la conferencia telef贸nica, los llamantes de EE.UU. pueden marcar (844) 850-0543, mientras que los llamantes internacionales deben usar (412) 317-5199. Se dispondr谩 de una grabaci贸n telef贸nica hasta el 30 de octubre de 2024, accesible marcando (877) 344-7529 desde EE.UU. o (412) 317-0088 desde el extranjero, utilizando el c贸digo de acceso a la grabaci贸n #9473630. La llamada tambi茅n se puede acceder a trav茅s de una retransmisi贸n en el sitio web de Viking, con un archivo disponible durante 30 d铆as.
Viking Therapeutics (NASDAQ: VKTX)電� 雽�靷� 氚� 雮措秳牍� 歆堩櫂鞐� 雽�頃� 靸堧鞖� 旃橂氩� 臧滊皽鞐� 欷戩爯鞚� 霊� 鞛勳儊 雼硠鞚� 靸濍 鞝滌暯 須岇偓搿�, 2024雲� 3攵勱赴 鞛 瓴瓣臣毳� 2024雲� 10鞗� 23鞚� 靾橃殧鞚� 鞁滌灔 膦呺 頉� 氚滍憸頃� 瓴冹澊霛缄碃 氚滍憸頄堨姷雼堧嫟. 須岇偓電� 臧欖潃 雮� 霃欕秬 響滌鞁� 鞓ろ泟 4鞁� 30攵�鞐� 鞚措煬頃� 瓴瓣臣毳� 雲检潣頃橁碃 鞚茧皹鞝侅澑 旮办梾 鞐呺嵃鞚错姼毳� 鞝滉车頃橁赴 鞙勴暣 鞝勴檾 須岇潣毳� 臧滌禍頃╇媹雼�.
鞝勴檾 須岇潣鞐� 彀胳棳頃橂牑氅�, 氙戈淡鞐愳劀電� (844) 850-0543鞙茧 鞝勴檾頃橁碃, 甑牅 鞝勴檾鞛愲姅 (412) 317-5199搿� 鞝勴檾頃挫暭 頃╇媹雼�. 鞝勴檾 雲轨潓鞚� 2024雲� 10鞗� 30鞚缄箤歆� 鞚挫毄 臧�電ロ晿氅�, 氙戈淡鞐愳劀電� (877) 344-7529鞙茧, 頃挫櫢鞐愳劀電� (412) 317-0088搿� 鞝勴檾頃橃棳 #9473630 雲轨潓 鞝戧芳 旖旊摐毳� 靷毄頃橃棳 鞝戧芳頃� 靾� 鞛堨姷雼堧嫟. 霕愴暅 Viking鞚� 鞗轨偓鞚错姼毳� 韱淀暣 鞗轨簮鞀ろ姼搿� 鞝戩啀頃� 靾� 鞛堨溂氅�, 30鞚� 霃欖晥 鞎勳勾鞚措笇臧� 鞝滉车霅╇媹雼�.
Viking Therapeutics (NASDAQ: VKTX), une entreprise biopharmaceutique en phase clinique ax茅e sur le d茅veloppement de nouvelles th茅rapies pour les troubles m茅taboliques et endocriniens, a annonc茅 qu'elle publiera ses r茅sultats financiers pour le troisi猫me trimestre de 2024 apr猫s la cl么ture du march茅 le mercredi 23 octobre 2024. L'entreprise organisera une conf茅rence t茅l茅phonique pour discuter de ces r茅sultats et fournir des mises 脿 jour g茅n茅rales sur l'entreprise 脿 16h30 heure de l'Est le m锚me jour.
Pour participer 脿 la conf茅rence t茅l茅phonique, les appelants am茅ricains peuvent composer le (844) 850-0543, tandis que les appelants internationaux doivent utiliser le (412) 317-5199. Un enregistrement t茅l茅phonique sera disponible jusqu'au 30 octobre 2024, accessible en composant le (877) 344-7529 depuis les 脡tats-Unis ou le (412) 317-0088 depuis l'茅tranger, en utilisant le code d'acc猫s 脿 l'enregistrement #9473630. L'appel peut 茅galement 锚tre accessible via la diffusion Web sur le site internet de Viking, avec un archive disponible pendant 30 jours.
Viking Therapeutics (NASDAQ: VKTX), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung neuartiger Therapien f眉r Stoffwechsel- und endokrine St枚rungen spezialisiert hat, hat angek眉ndigt, dass es seine Finanzergebnisse f眉r das dritte Quartal 2024 nach Marktschluss am Mittwoch, den 23. Oktober 2024 ver枚ffentlichen wird. Das Unternehmen wird am selben Tag um 16:30 Uhr Eastern Time eine Telefonkonferenz abhalten, um diese Ergebnisse zu diskutieren und allgemeine Unternehmensaktualisierungen bereitzustellen.
Um an der Telefonkonferenz teilzunehmen, k枚nnen US-Anrufer (844) 850-0543 w盲hlen, w盲hrend internationale Anrufer (412) 317-5199 verwenden sollten. Eine Telefonaufzeichnung wird bis zum 30. Oktober 2024 verf眉gbar sein und ist erreichbar unter (877) 344-7529 aus den USA oder (412) 317-0088 aus dem Ausland, unter Verwendung des Zugangs Codes zur Aufnahme #9473630. Der Anruf kann auch per Webcast 眉ber die Website von Viking abgerufen werden, mit einem Archiv, das 30 Tage verf眉gbar ist.
- None.
- None.
Conference Call Scheduled for Wednesday, October 23 at 4:30 p.m. Eastern Time听
The company will host a conference call to discuss financial results and general corporate updates beginning at 4:30 p.m. Eastern Time on Wednesday, October 23, 2024. To participate on the conference call, please dial (844) 850-0543 from the
About Viking Therapeutics, Inc.听
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders, with three compounds currently in clinical trials.听Viking's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives.听Viking's clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the potential treatment of various metabolic disorders. Data from a Phase 1 and a Phase 2 trial evaluating VK2735 (dosed subcutaneously) for metabolic disorders demonstrated an encouraging safety and tolerability profile as well as positive signs of clinical benefit. Concurrently, the company is evaluating an oral formulation of VK2735 in a Phase 1 trial. Viking is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. The compound successfully achieved both the primary and secondary endpoints in a recently completed Phase听2b听study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis.听In a Phase 2a trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared with patients who received placebo.听The company's newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists (or DACRAs) for the treatment of obesity and other metabolic disorders.听 In the rare disease space, Viking is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD).听 In a Phase听1b听clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD, VK0214 was shown to be safe and well-tolerated, while driving significant reductions in plasma levels of very long-chain fatty acids (VLCFAs) and other lipids, as compared to placebo.
For more information about Viking Therapeutics, please visit听.
听
View original content to download multimedia:
SOURCE Viking Therapeutics, Inc.
FAQ
When will Viking Therapeutics (VKTX) report its Q3 2024 financial results?
What time is Viking Therapeutics' (VKTX) Q3 2024 earnings call scheduled for?
How can investors participate in Viking Therapeutics' (VKTX) Q3 2024 earnings call?
Until what date will the replay of Viking Therapeutics' (VKTX) Q3 2024 earnings call be available?
